The agency announces that 81 medicines overall were recommended in 2016.
The European Medicines Agency (EMA) recommended seven new medicines for marketing authorization at its December 2016 meeting, bringing the total on recommendations to 81 for 2016. The new drugs target forms of arthritis, lung cancer, non-Hodgkin’s lymphoma, hemophilia, and epilepsy, among other conditions.
EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended granting market authorization for the following:
CHMP also recommended extending indications for Ameluz, Cinryze, Ilaris, Jardiance, Jentadueto, Keytruda, Tivacy, Trajenta and Votubia.
Source: EMA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
2 Commerce Drive
Cranbury, NJ 08512